Energy News / Shareholders Foundation, Inc.

NASDAQ:NBRV Shareholder Notice: Lawsuit Alleges Misleading Statements by Nabriva Therapeutics Plc

Via: ReleaseWire

Updated 12:00 PM CDT, Tue, May 21,2019

A lawsuit was filed on behalf of investors in Nabriva Therapeutics plc (NASDAQ: NBRV) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 05/21/2019 -- An investor, who purchased shares of Nabriva Therapeutics plc (NASDAQ: NBRV), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Nabriva Therapeutics plc.

Investors who purchased shares of Nabriva Therapeutics plc (NASDAQ: NBRV) have certain options and for certain investors are short and strict deadlines running. Deadline: July8, 2019. NASDAQ: NBRV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On April 30, 2019, Nabriva Therapeutics plc revealed that it had received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") for its New Drug Application ("NDA") for CONTEPO™ (fosfomycin) for injection for the treatment of complicated urinary tract infections. According to the CRL, Nabriva Therapeutics plc had to address certain "issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers" before the FDA would approve the NDA.

The plaintiff claims that between November 1, 2018 and April 30, 2019, the Defendants failed to disclose to investors that the Company's manufacturers failed to meet good manufacturing practices, that these manufacturers would be subject to inspections by the FDA in connection with the Company's NDA, that, as a result of the manufacturing deficiencies, the Company's NDA for CONTEPO was unlikely to be approved by the FDA; and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Nabriva Therapeutics plc (NASDAQ: NBRV) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqnbrv-shareholder-notice-lawsuit-alleges-misleading-statements-by-nabriva-therapeutics-plc-1220704.htm

Media Relations Contact
Michael Daniels
1-858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com